[Pilot study of concomitant TS-1/CDGP radiotherapy for esophageal cancer].
Although surgery is treatment of choice for esophageal cancer, radiochemotherapy is being employed throughout Japan for the purpose of improving patient QOL. The results of this therapy are reported to be comparable to those associated with surgical treatment. However, since concomitant 5-FU/CDDP radiotherapy, currently the treatment of choice when implementing radiochemotherapy, is associated with a comparatively high incidence of gastrointestinal disorders and requires continuous intravenous infusion for 24 hours, it lowers the level of patient QOL. We have proposed a clinical study of concomitant TS-1/CDGP radiotherapy for the purpose of maintaining patient QOL and improving outcome. We conducted a pilot study prior to the phase I and II studies. The study was conducted on six cases and favorable results were obtained, consisting of a CR rate of 66.7% and a two-year survival rate of 50%. Although bone marrow inhibition was observed as an adverse side effect, gastrointestinal disorders that were discernible to the patients were extremely mild, and patient QOL was able to be maintained. CR was observed in 2 cases who were positive for DPD as determined by immunostaining. We are planning on conducting phase I and II studies in the future based on the potential for this treatment to contribute to the preservation of patient QOL and improve prognosis.
Inaba
Hiroyuki
H
Division of Gastroenterology and Hepatology, Dept. of Internal Medicine, St. Marianna University, School of Medicine.
Miyazaki
Aya
A
Tsuda
Takashi
T
Akasaka
Hiroko
H
Kobayashi
Miyako
M
Okamoto
Masaru
M
Ogihara
Kyouko
K
Yamauchi
Shunichi
S
Koro
Takeshi
T
Katoh
Naoyuki
N
Fujita
Kazuyuki
K
Watanabe
Yoshiyuki
Y
Abiko
Ryuichi
R
Nakaya
Shinichi
S
Kitajima
Satoshi
S
Hoshikawa
Yoshikazu
Y
Kimura
Masayuki
M
Itoh
Fumio
F
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D004338:Drug Combinations; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000523:psychology / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D008297:Male; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D010094:Oxonic Acid / Q000008:administration & dosage; D010865:Pilot Projects; D011725:Pyridines / Q000008:administration & dosage; D011788:Quality of Life; D015996:Survival Rate; D005641:Tegafur / Q000008:administration & dosage
D004338:Drug Combinations; D009944:Organoplatinum Compounds; D011725:Pyridines; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; C053989:nedaplatin